Philadelphia, PA, United States of America

Mikel D Ghelfi

This inventor holds 1 USPTO granted patent. Top assignee: University of Pennsylvania. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mikel D Ghelfi. Retrieved from https://idiyas.com/inventor/mikel-d-ghelfi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mikel D. Ghelfi: Inventor in Biomedical Research

Introduction

Mikel D. Ghelfi is an inventor based in Philadelphia, Pennsylvania. His patent work is associated with the University of Pennsylvania and focuses on methods for studying translation readthrough in biomedical research.

Latest Patents

Ghelfi is named on one patent, titled “High Throughput Assays for Detecting Translation Readthrough Inducers.” The invention concerns assays designed to identify compounds that induce translation readthrough, a process in which cellular protein-making machinery continues past a stop signal in genetic instructions.

Career Highlights

Ghelfi’s recorded patent activity connects his work with the University of Pennsylvania, a research institution in Philadelphia. His listed portfolio includes 1 patent.

Collaborations

The patent’s association with the University of Pennsylvania reflects a connection to the university’s research environment. The available information does not identify additional collaborators.

Conclusion

Mikel D. Ghelfi’s patent work centers on high-throughput methods for detecting translation readthrough inducers, linking his invention to biomedical research at the University of Pennsylvania.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…